EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fundus Autofluorescence as a Sensitive Biomarker of Disease Progression in Bietti Crystalline Dystrophy

Huanyu Zhao, Masatoshi Fukushima, Takahiro Hisai, Yan Tao, Sakurako Shimokawa, Kaho Yamamoto, Yoshito Koyanagi, Koh-Hei Sonoda, Takaaki Hayashi, Shinji Ueno, Manabu Miyata, Kaoru Fujinami und 3 weitere

Ophthalmology Science · 2026-05 · 6 (5) · 101166

DOI: 10.1016/j.xops.2026.101166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology Science, 2026-05. Verfasst von Huanyu Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Cell Science Research Foundation, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To characterize the natural history of Bietti crystalline dystrophy (BCD) and to identify reliable outcome measures for detecting disease progression.

Design

A multicenter, prospective observational study.

Participants

Patients with genetically confirmed BCD carrying biallelic pathogenic CYP4V2 variants, recruited from 6 academic centers in Japan, with a best-corrected visual acuity (BCVA) of 1.0 logarithm of the minimum angle of resolution (logMAR) or better in ≥1 eye at baseline.

Methods

Multimodal imaging and functional assessments included BCVA, static perimetry (Humphrey 10-2), fundus autofluorescence, and OCT. Main Outcome Measures: Longitudinal changes in BCVA; hypo-autofluorescent (hypo-AF) area; and static perimetry parameters, such as mean deviation (MD), absolute scotoma points (ASPs), transitional zone retinal sensitivity (TZRS), and central subfield thickness (CST).

Results

Thirteen patients with genetically confirmed BCD were followed prospectively over a median of 2.5 years (range: 2.5-3 years). Longitudinal analysis showed progression in hypo-AF area (12.0 mm2/year, 95% confidence interval [CI]: 7.1 to 16.9, P = 0.003), CST (-4.3 μm/year, 95% CI: -6.6 to -2.1, P < 0.001), MD (-1.0 dB/year, 95% CI: -1.7 to -0.3, P = 0.02), ASP (2.4 points/year, 95% CI: 1.8-3.0, P < 0.001), TZRS (-2.1 dB/year, 95% CI: -2.8 to -1.4, P < 0.001), and BCVA (0.04 logMAR/year, 95% CI: 0.01-0.07, P = 0.01). The hypo-AF area showed the biggest annual change rate (21.6%) and highest signal-to-noise ratio (1.10) among all parameters. Linear mixed-effects models revealed that hypo-AF area progression was significantly associated with faster loss of MD (P = 0.01) and ASP (P = 0.004), but not with BCVA, TZRS, and CST changes.

Conclusions

This prospective natural history study suggests that hypo-AF area may serve as a useful structural measure for detecting disease progression in BCD clinical trials, warranting further validation in larger prospective studies. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

Stichwörter der Autor:innen

Bietti crystalline dystrophy (BCD)BiomarkerDisease progressionFundus autofluorescence (FAF)Hypo autofluorescent area

Autor:innen und Institutionen

  • Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Ophthalmology, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan.
  • Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.
  • Department of Medical Genetics, NHO Tokyo Medical Center, Tokyo, Japan.

Förderung

  • The Cell Science Research Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Zhao, H., Fukushima, M., Hisai, T., Tao, Y., Shimokawa, S., Yamamoto, K., Koyanagi, Y., Sonoda, K. H., Hayashi, T., Ueno, S., Miyata, M., Fujinami, K., Tsunoda, K., Oishi, A., & Murakami, Y. (2026). Fundus Autofluorescence as a Sensitive Biomarker of Disease Progression in Bietti Crystalline Dystrophy. Ophthalmology Science, 6(5), 101166. https://doi.org/10.1016/j.xops.2026.101166

Vancouver

Zhao H, Fukushima M, Hisai T, Tao Y, Shimokawa S, Yamamoto K, et al. Fundus Autofluorescence as a Sensitive Biomarker of Disease Progression in Bietti Crystalline Dystrophy. Ophthalmology Science. 2026;6(5):101166. doi:10.1016/j.xops.2026.101166

BibTeX
@article{Zhao2026,
  author = {Zhao, Huanyu and Fukushima, Masatoshi and Hisai, Takahiro and Tao, Yan and Shimokawa, Sakurako and Yamamoto, Kaho and Koyanagi, Yoshito and Sonoda, Koh-Hei and Hayashi, Takaaki and Ueno, Shinji and Miyata, Manabu and Fujinami, Kaoru and Tsunoda, Kazushige and Oishi, Akio and Murakami, Yusuke},
  title = {Fundus Autofluorescence as a Sensitive Biomarker of Disease Progression in Bietti Crystalline Dystrophy},
  journal = {Ophthalmology Science},
  year = {2026},
  volume = {6},
  number = {5},
  pages = {101166},
  doi = {10.1016/j.xops.2026.101166}
}
Kostenlos starten →